source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Investors Business Daily | 2022-11-30 14:29:26 | https://www.investors.com/research/the-income-investor/top-dividend-stocks-leading-biotech-abbvie-hikes-payout/ | With a long track record of payouts, top dividend stock AbbVie is once again in focus, generating a strong yield with stable fundamentals The post Top Dividend Stocks: Leading Biotech AbbVie Hikes Payout appeared first on Investor's Business Daily. | Top Dividend Stocks: Leading Biotech AbbVie Hikes Payout | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-30 08:05:00 | https://www.fool.com/investing/2022/11/30/3-top-dividend-kings-to-buy-for-the-long-haul/ | Dividend stocks are an easy option to boost income. | 3 Top Dividend Kings to Buy for the Long Haul | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-11-29 13:57:03 | https://seekingalpha.com/article/4561180-abbvie-inc-abbv-5th-annual-evercore-isi-healthconx-conference-2022-transcript | AbbVie Inc. (NYSE:ABBV ) 5th Annual Evercore ISI HealthCONx Conference Call November 29, 2022 10:55 AM ET Company Participants Jeff Stewart - Chief Commercial Officer Scott Reents - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Gavin Clark-Gartner All right. Welcome, everyone. | AbbVie Inc. (ABBV) 5th Annual Evercore ISI HealthCONx Conference 2022 - (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-11-28 09:02:17 | https://www.zacks.com/stock/news/2022698/here-s-what-s-driving-abbvie-s-abbv-outperformance-this-year | AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential. | Here's What's Driving AbbVie's (ABBV) Outperformance This Year | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-27 08:53:00 | https://www.fool.com/investing/2022/11/27/8-dividend-aristocrats-to-buy-now-for-a-lifetime-o/ | Dividend stocks are a great way to protect against a downturn and these are the cream of the crop. | 8 Dividend Aristocrats to Buy Now for a Lifetime of Passive Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-11-27 07:00:00 | https://seekingalpha.com/article/4560663-5-great-dividend-aristocrats | It seems that the "crypto craze" is now a blast from the past. And tech stocks are no longer in vogue. | 5 Great Dividend Aristocrats To Help You Sleep Well At Night | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-26 08:15:00 | https://www.fool.com/investing/2022/11/26/better-dividend-stock-abbvie-or-viatris/ | These pharmaceutical companies are profitable and offer above-average dividends. | Better Dividend Stock: AbbVie or Viatris? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-26 06:05:00 | https://www.fool.com/investing/2022/11/26/3-dividend-stocks-to-hold-forever/ | These businesses -- and dividends -- are built to last. | 3 Dividend Stocks to Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Investors Business Daily | 2022-11-25 14:10:15 | https://www.investors.com/stock-lists/ibd-50/hot-biotech-stocks-rise-into-leadership-pass-buy-points-or-build-bases/ | Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases. | Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-11-25 10:32:22 | https://www.zacks.com/stock/news/2022287/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know | AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2022-11-23 14:52:46 | https://marijuanastocks.com/2-marijuana-stocks-to-buy-right-now-before-2023/ | The Best Marijuana Stocks Investors Are Watching The post 2 Marijuana Stocks To Buy Right Now Before 2023? appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | 2 Marijuana Stocks To Buy Right Now Before 2023? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-23 11:30:00 | https://www.fool.com/investing/2022/11/23/want-10000-in-annual-dividend-income-by-retirement/ | This is a stock that rewards long-term investors through continual dividend increases. | Want $10,000 in Annual Dividend Income by Retirement? Here's How Much You Should Invest in AbbVie Today. | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Investors Business Daily | 2022-11-23 08:00:48 | https://www.investors.com/etfs-and-funds/etfs/sp500-top-investors-reveal-7-high-dividend-stocks-you-should-own/ | High-dividend ETFs are just about the only diversified funds up this year. And most of them agree on the S&P 500 stocks you need to own. | Top Investors Reveal 7 High-Dividend Stocks You Should Own | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2022-11-23 06:00:00 | https://www.forbes.com/sites/greatspeculations/2022/11/23/this-pharmaceutical-company-is-a-better-pick-over-johnson--johnson-stock/ | While ABBV may outperform JNJ in the next three years, it is helpful to see how Johnson & Johnson's Peers fare on metrics that matter. | This Pharmaceutical Company Is A Better Pick Over Johnson & Johnson Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-23 05:20:00 | https://www.fool.com/investing/2022/11/23/abbvie-boosts-its-dividend-is-the-dividend-king-a/ | Shares of the pharmaceutical stock have left the S&P 500 index in the dust so far this year. | AbbVie Boosts Its Dividend: Is the Dividend King a Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-22 09:45:00 | https://www.fool.com/investing/2022/11/22/2-reasons-to-buy-abbvie-stock-and-1-reason-to-sell/ | The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem. | 2 Reasons to Buy AbbVie Stock and 1 Reason to Sell | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2022-11-22 09:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-piper-sandler-healthcare-conference-301684500.html | NORTH CHICAGO, Ill. , Nov. 22, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. | AbbVie to Present at the Piper Sandler Healthcare Conference | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-11-22 07:32:20 | https://www.zacks.com/stock/news/2020710/abbvie-abbv-bla-for-epcoritamab-gets-fda-priority-tag | The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL. | AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-22 06:00:00 | https://www.fool.com/investing/2022/11/22/want-passive-income-2023-buy-these-dividend-kings/ | These stocks offer you a gift: recurrent income just for owning them. | Want Passive Income in 2023? Buy These Dividend Kings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-11-22 04:05:36 | https://seekingalpha.com/article/4559750-abbvie-paid-wait | AbbVie is a global biopharmaceutical company with a large portfolio of drugs and therapies. Its most successful drug, Humira, is facing a loss of exclusivity in 2023. | AbbVie: Paid To Wait | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Kiplinger | 2022-11-16 13:20:04 | https://www.kiplinger.com/investing/stocks/best-value-stocks | A roller-coaster year has sent a lot of deserving names into bargain territory. Here are nine value stocks for investors to consider as we head into 2023. | 9 Best Value Stocks to Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2022-11-16 08:11:57 | https://www.marketbeat.com/originals/can-abbvie-grow-revenue-when-humira-biosimilars-hit-the-market/?SNAPI | Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry. | Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-11-15 14:03:09 | https://seekingalpha.com/article/4558075-abbvie-inc-abbv-presents-4th-annual-wolfe-research-healthcare-conference | AbbVie Inc. | AbbVie Inc. (ABBV) Presents at 4th Annual Wolfe Research Healthcare Conference | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-11-15 13:00:00 | https://stockmarket.com/featured/3-pharmaceutical-stocks-for-your-november-2022-watchlist-2022-11-15 | 3 pharmaceutical stocks to watch in the stock market right now. | 3 Pharmaceutical Stocks For Your November 2022 Watchlist | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-11-14 10:32:35 | https://www.zacks.com/stock/news/2017778/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know | AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-13 06:00:00 | https://www.fool.com/investing/2022/11/13/2-top-stocks-to-buy-in-november-and-hold-forever/ | Today is a great time to enter these long-term stories. | 2 Top Stocks to Buy in November and Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-11-10 12:59:49 | https://investorplace.com/2022/11/7-no-brainer-dividend-stocks-to-buy-for-2023-and-beyond/ | With the monetary paradigm shifting beneath our feet, investors have every reason to consider no-brainer dividend stocks to buy for 2023 and beyond. This is no marketing gimmick – folks need to avoid paralysis by analysis and direct their portfolios based on intuitive dynamics. | 7 No-Brainer Dividend Stocks to Buy for 2023 and Beyond | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-09 10:05:00 | https://www.fool.com/investing/2022/11/09/if-you-like-dividends-you-should-love-these-stocks/ | These stocks are crushing the market this year and still have tremendous profit potential. | If You Like Dividends, You Should Love These 3 Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-09 06:00:00 | https://www.fool.com/investing/2022/11/09/healthcare-stock-disappointed-why-its-still-a-buy/ | AbbVie's strong portfolio has what it takes to drive long-term growth. | This Healthcare Stock Disappointed Investors. Here's Why It's Still a Buy. | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-08 07:45:00 | https://www.fool.com/investing/2022/11/08/investing-1000-in-the-current-market-dont-overlook/ | Just because the stock market is going haywire doesn't mean you have to sit on the sidelines. | Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-05 09:31:00 | https://www.fool.com/investing/2022/11/05/3-no-brainer-dividend-stocks-to-buy-in-november/ | There's no need for agonizing decision-making with these great dividend stocks. | 3 No-Brainer Dividend Stocks to Buy in November | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-05 09:23:00 | https://www.fool.com/investing/2022/11/05/3-reasons-to-buy-abbvie-stock-right-now/ | The drugmaker has something to offer to all kinds of investors. | 3 Reasons to Buy AbbVie Stock Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-11-04 16:33:05 | https://www.zacks.com/stock/news/2014383/3-dividend-kings-crushing-the-s-p-500-in-2022 | Companies in the Dividend King club carry well-established and successful business operations, clearly displayed by their commendable commitment to shareholders over decades of increased dividend payouts. | 3 Dividend Kings Crushing the S&P 500 in 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-04 08:15:00 | https://www.fool.com/investing/2022/11/04/better-buy-abbvie-vs-walgreens-boots-alliance/ | Both these companies pay a dividend, but the similarities stop there. | Better Buy: AbbVie vs. Walgreens Boots Alliance | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-03 05:52:00 | https://www.fool.com/investing/2022/11/03/why-dividend-investors-can-still-buy-abbvie-stock/ | The big-pharma company's dividend remains safe and sound. | Why Dividend Investors Can Still Buy AbbVie Stock With No Worries | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-11-02 10:33:11 | https://www.zacks.com/stock/news/2012552/5-stocks-to-watch-on-recent-dividend-hikes-amid-high-volatility | Investors may keep a tab on ABBV, ASTE, BCC, ESQ and HIG, which have lately hiked their dividend payments to reward investors. | 5 Stocks to Watch on Recent Dividend Hikes Amid High Volatility | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-11-01 10:32:32 | https://www.zacks.com/stock/news/2011661/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it | Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-11-01 08:45:00 | https://www.fool.com/investing/2022/11/01/these-2-passive-income-stars-just-declared-dividen/ | It's been a good year for these two titans in their respective sectors -- hence the generosity. | These 2 Passive Income Stars Just Declared Dividend Raises | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-10-31 23:35:56 | https://seekingalpha.com/article/4551285-deal-activity-could-jumpstart-biotechnology | Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID-19 revenues have significantly improved the funding positions of many large biopharma companies, providing ample dry po... | Deal Activity Could Jumpstart Biotechnology | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2022-10-31 01:00:11 | https://www.marketbeat.com/originals/why-is-abbvie-stock-falling-but-still-good-long-term/?SNAPI | Why is AbbVie stock dropping today but still a solid investment? Its solid base, robust pipeline and dividend support a long position in ABBV stock. | Why is AbbVie Stock Falling, but Still Good Long-Term? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Barrons | 2022-10-29 07:00:00 | https://www.barrons.com/articles/exxon-dividends-stock-abbvie-visa-51666983431 | Energy giant Exxon Mobil, pharmaceutical firm AbbVie, and cards firm Visa were among the U.S. companies that announced dividend increases last week. | Exxon Mobil, AbbVie, and Visa Raised Dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo Finance | 2022-10-28 18:00:14 | https://www.youtube.com/watch?v=oR7Kq_cDlB0 | Health care reporter Anjalee Khemlani outlines how inflation and supply and demand issues are putting the squeeze on AbbVie's Botox treatments. | AbbVie's Botox faces demand issues as prices soar | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-10-28 17:55:21 | https://seekingalpha.com/article/4550579-abbvie-5-aspects-of-q3-earnings-persuading-me-to-buy-the-dip | AbbVie released its Q322 earnings today. Revenue of $14.8bn slightly missed analysts expectations. Earnings per share increased by 24% on a diluted basis and 29% on an adjusted basis however. | AbbVie - 5 Aspects Of Q3 Earnings Persuading Me To "Buy The Dip" | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-10-28 14:25:00 | https://www.youtube.com/watch?v=dIewp1114cE | Gina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three stocks Sanchez is interested in buying and one the strategist is bailing on. | Three buys and a bail: AbbVie, Eli Lilly, Humana and Moderna | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-10-28 14:18:20 | https://www.zacks.com/stock/news/2010713/abbvie-abbv-beats-on-q3-earnings-lags-sales-narrows-22-view | AbbVie's earnings (ABBV) beat estimates for third-quarter 2022, while sales miss the same. Shares drop in pre-market trading after it narrows down its full-year earnings guidance. | AbbVie (ABBV) Beats on Q3 Earnings, Lags Sales, Narrows '22 View | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-10-28 14:17:24 | https://investorplace.com/2022/10/7-most-popular-dividend-stocks-ranked-by-market-cap/ | This article will give you seven of the most popular dividend stocks ranked from the largest market cap to the smallest. Dividend stocks have a place in every investor's portfolio. | The 7 Most Popular Dividend Stocks Ranked from Biggest to Smallest | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-10-28 12:23:04 | https://seekingalpha.com/article/4550412-abbvie-inc-abbv-q3-2022-earnings-call-transcript | AbbVie Inc. (NYSE:ABBV ) Q3 2022 Earnings Conference Call October 28, 2022 9:00 AM ET Company Participants Liz Shea – Vice President-Investor Relations Rick Gonzalez – Chairman of the Board and Chief Executive Officer Jeff Stewart – Executive Vice President and Chief Commercial Officer Tom Hudson – Senior Vice Presiden... | AbbVie Inc. (ABBV) Q3 2022 Earnings Call Transcript | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2022-10-28 08:02:52 | https://www.marketwatch.com/story/abbvie-narrows-guidance-for-2022-2022-10-28 | Shares of AbbVie Inc. ABBV, +0.65% fell 2.9% in premarket trading on Friday after the company trimmed guidance for adjusted earnings per share for the year. AbbVie had earnings of $3.9 billion, or $2.21 per share, in the third quarter of 2022, compared with $3.2 billion, or $1.78 per share, in the same quarter a year a... | AbbVie narrows guidance for 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-10-27 21:04:07 | https://www.zacks.com/stock/news/2000105/pfizer-earnings-preview-growth-diversification-is-key | Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter. | Pfizer Earnings Preview: Growth & Diversification is Key | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-10-27 17:18:05 | https://www.zacks.com/stock/news/1998894/abbvie-q3-preview-can-shares-continue-their-run | AbbVie shares have been a bright spot in a dim market year-to-date, up a double-digit 17% and easily crushing the S&P 500's performance. | AbbVie Q3 Preview: Can Shares Continue Their Run? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-10-26 14:18:07 | https://www.zacks.com/stock/news/1997913/will-abbvie-s-immunology-drugs-continue-to-drive-q3-earnings | AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products. | Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-26 05:30:00 | https://www.fool.com/investing/2022/10/26/2-monster-stocks-to-buy-without-any-hesitation/ | These stocks are crushing the bear market. | 2 Monster Stocks to Buy Without Any Hesitation | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-24 08:10:00 | https://www.fool.com/investing/2022/10/24/3-stocks-to-avoid-this-week/ | These investments seem pretty vulnerable right now. | 3 Stocks to Avoid This Week | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2022-10-24 07:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-data-from-extensive-portfolio-at-american-college-of-gastroenterology-annual-scientific-meeting-301656494.html | Data illustrates AbbVie's commitment to providing research and innovative solutions that support patients with high disease burden and unmet need Oral presentations address treatment of moderate to severe Crohn's disease, including efficacy and safety outcomes from the SKYRIZI® (risankizumab-rzaa) pivotal clinical prog... | AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-22 09:45:00 | https://www.fool.com/investing/2022/10/22/3-healthcare-stocks-that-are-too-cheap-to-ignore/ | They all offer attractive dividends, too. | 3 Healthcare Stocks That Are Too Cheap to Ignore | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-10-21 13:33:19 | https://www.zacks.com/stock/news/1995802/abbvie-abbv-to-boost-immunology-pipeline-with-new-acquisition | AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio. | AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-10-21 07:05:00 | https://seekingalpha.com/article/4547837-abbvie-the-investors-trifecta | It is well-known that AbbVie loses its US patent protection for Humira in 2023. Humira international sales have fallen sharply after already losing patent protection and the same will be expected in the US. | AbbVie: The Investor's Trifecta | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-21 05:23:00 | https://www.fool.com/investing/2022/10/21/which-stock-is-more-likely-to-10x-first-moderna-or/ | Both companies are developing new drugs but that's where the similarities stop. | Which Stock Is More Likely to Double Your Money First: Moderna or AbbVie? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-18 05:28:00 | https://www.fool.com/investing/2022/10/18/stock-more-likely-5x-first-abbvie-tilray-brands/ | These two growth stocks should take very different trajectories as they expand. | Which Stock Is More Likely to 5X First: AbbVie or Tilray Brands? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-17 09:57:11 | https://www.fool.com/investing/2022/10/17/stocks-i-own-and-will-buy-more-of-if-market-crash/ | It's time to make a wishlist -- and just in time for the holidays! | 4 Stocks I Own and Will Buy More of if the Market Crashes | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-17 05:23:00 | https://www.fool.com/investing/2022/10/17/3-dividend-stocks-to-buy-now-for-a-lifetime-of-pas/ | These ultra-reliable businesses could deliver quarterly payments that steadily grow throughout your retirement. | 3 Dividend Stocks to Buy Now for a Lifetime of Passive Income | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-16 06:41:00 | https://www.fool.com/investing/2022/10/16/3-supercharged-dividend-stocks-to-buy-if-theres-a/ | All three of these medical stocks offer a high-yield dividend. | 3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2022-10-14 07:30:37 | https://marijuanastocks.com/top-medical-and-ancillary-marijuana-stocks-for-q4-2022/ | Top Ancillary and Medical Pot Stocks Right Now? The post Top Medical and Ancillary Marijuana Stocks For Q4 2022 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Top Medical and Ancillary Marijuana Stocks For Q4 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-13 05:05:00 | https://www.fool.com/investing/2022/10/13/3-dividend-stocks-that-could-pay-you-for-the-rest/ | All three of the stocks are Dividend Aristocrats. | 3 Dividend Stocks That Could Pay You for the Rest of Your Life | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-10-11 16:15:17 | https://investorplace.com/2022/10/4-dividend-stocks-yielding-4/ | The market continues its downward trend. The U.S. Federal Reserve is raising interest rates in response to high inflation. | 4 Dividend Stocks Yielding 4%+ | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-10-11 11:40:46 | https://seekingalpha.com/article/4545906-top-dividend-king-stocks | Dividend kings are elite stocks that have raised dividends for at least 50 consecutive years. Naturally, their track record attracts pickers of top income stocks. Below, I show how we screen the dividend kings for two actionable best ideas, one each for high-yield and dividend growth investors. | Top Dividend King Stocks To Watch - Our Favorites Are Altria And AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-11 06:04:00 | https://www.fool.com/investing/2022/10/11/better-bear-market-buy-abbott-laboratories-vs-abbv/ | It's parent vs. child in this bear-market matchup. | Better Bear-Market Buy: Abbott Laboratories vs. AbbVie Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-10-10 06:15:48 | https://investorplace.com/2022/10/7-biotech-stocks-set-to-boom-2023/ | Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure. | These 7 Biotech Stocks Are Set to Boom in 2023 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-09 09:45:00 | https://www.fool.com/investing/2022/10/09/2-top-healthcare-stocks-defying-the-bear-market/ | Both companies have revenue rolling in today, and they both expect loads more in the near term. | 2 Top Healthcare Stocks Defying the Bear Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-10-08 07:00:00 | https://seekingalpha.com/article/4545362-3-dividend-growth-stocks-to-fight-inflation | Dividend growth stocks are my favorite investment category – no matter what kind of economic cycle we're in. I can collect (or, better yet, reinvest) their payouts even when the market is going through volatility. | 3 Dividend Growth Stocks To Fight Inflation | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-08 06:05:00 | https://www.fool.com/investing/2022/10/08/3-great-dividend-stocks-to-buy-in-october/ | Their dividends should be much bigger in the future. | 3 Great Dividend Stocks to Buy in October | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-10-07 08:46:19 | https://investorplace.com/growth-stocks-to-buy-and-hold/ | A bear market is the worst time to buy growth stocks. Volatility spooks investors, and current fears around inflation and higher interest rates also hurt the story. | 7 Growth Stocks to Buy and Hold for the Next 10 Years | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-10-07 07:05:46 | https://247wallst.com/investing/2022/10/07/7-strong-buy-dividend-kings-to-grab-now-in-case-a-total-market-meltdown-is-coming/ | At 24/7 Wall St., we know how important dividend size, stability and growth are to growth and income investors who need a dependable stream of passive income. | 7 ‘Strong Buy' Dividend Kings to Grab Now in Case a Total Market Meltdown Is Coming | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-06 10:30:00 | https://www.fool.com/investing/2022/10/06/why-warren-buffett-thinks-its-a-mistake-to-dump-yo/ | Being out of the stock market may seem safer right now, but it is far from a risk-free strategy. | Why Warren Buffett Thinks It's a Mistake to Dump Your Stocks in a Bear Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-10-05 14:15:52 | https://investorplace.com/2022/10/best-stocks-2022-whats-not-to-like-about-abbvie-abbv-stock/ | The stock market is rolling over as the third quarter comes to a close. The S&P 500 is down 21% year-to-date (YTD) as of this writing. | Best Stocks 2022: What's Not to Like About AbbVie (ABBV) Stock? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-05 06:11:00 | https://www.fool.com/investing/2022/10/05/3-dividend-stocks-to-buy-in-october-and-hold-forev/ | The payouts these companies distribute every quarter could surge over the next several years. | 3 Dividend Stocks to Buy In October and Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-10-04 17:39:06 | https://investorplace.com/2022/10/3-cheap-stocks-to-buy-for-their-high-cash-flow-and-dividends/ | Living through bear markets sure can be tough. Such environments can create a lot of emotional turmoil, heartache and painful losses. | 3 Cheap Stocks to Buy for Their High Cash Flow and Dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-10-04 10:32:28 | https://www.zacks.com/stock/news/1987782/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock | Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store. | Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-10-03 23:40:00 | https://seekingalpha.com/article/4544489-five-expected-dividend-increases-in-october-2022 | Making sure that income stream grows is critical. Without growth, your dividend income stream will lose purchasing power to inflation. | Five Expected Dividend Increases In October 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-10-03 11:17:47 | https://www.zacks.com/stock/news/1987548/can-abbvie-s-abbv-new-drugs-make-up-for-lost-humira-sales | AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023. | Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-10-03 11:00:00 | https://stockmarket.com/featured/best-stocks-to-buy-during-a-recession-3-defensive-stocks-to-know-2022-10-03 | Are these defensive stocks the best stocks to buy during a recession? | Best Stocks To Buy During A Recession? 3 Defensive Stocks To Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-02 10:37:00 | https://www.fool.com/investing/2022/10/02/got-2000-buy-these-2-bear-market-beating-growth-st/ | Neither company has any reason to worry about a recession either. | Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-10-01 08:10:00 | https://www.fool.com/investing/2022/10/01/why-this-dividend-king-is-a-buy-abbvie/ | Shares of this drugmaker have far outpaced the S&P 500 index in 2022. | Here's Why This Dividend King Is a Buy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-30 06:00:00 | https://www.fool.com/investing/2022/09/30/where-will-abbvie-be-in-3-years/ | This company has defied the bear market. | Where Will AbbVie Be in 3 Years? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-27 07:17:00 | https://www.fool.com/investing/2022/09/27/is-loading-up-on-passive-income-stocks-right-now-a/ | Juicy yields aren't the only factor to consider. | Is Loading Up on Passive Income Stocks Right Now a Good Idea? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-09-26 15:06:14 | https://stockmarket.com/featured/good-stocks-to-buy-right-now-4-healthcare-stocks-to-know-2022-09-26 | 4 top healthcare stocks for your second-half of 2022 watchlist. | Good Stocks To Buy Right Now? 4 Healthcare Stocks To Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-25 05:57:00 | https://www.fool.com/investing/2022/09/25/3-dividend-aristocrats-warren-buffett-buy-now/ | A little-known group of Buffett stocks includes three members of dividend royalty with solid growth prospects. | 3 Dividend Aristocrats In Warren Buffett's Secret Portfolio You Can Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Investors Business Daily | 2022-09-24 08:00:00 | https://www.investors.com/news/sp-500-giant-leads-5-stocks-showing-strength-in-bear-market/ | S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market. The post S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market appeared first on Investor's Business Daily. | S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-24 06:41:00 | https://www.fool.com/investing/2022/09/24/is-abbvie-a-buy/ | The pharma stock has been outperforming the market this year. | Is AbbVie a Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-09-23 15:50:38 | https://www.youtube.com/watch?v=LETqD_LBpw4 | CNBC's Bertha Coombs reports on health care stocks. | Drugmaker stocks lead sector with healthy dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-09-23 09:19:05 | https://www.youtube.com/watch?v=zRkvFrS3g8Y | The healthcare sector is an investor favorite in a defensive market. CNBC's Bertha Coombs joins 'Squawk Box' to break down some players with the best dividend yields. | Health care stocks with dividend yields to weather through market turmoil | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-23 06:22:00 | https://www.fool.com/investing/2022/09/23/use-these-3-simple-tricks-to-maximize-your-returns/ | These strategies will work for other large biopharmas, too. | Use These 3 Simple Tricks to Maximize Your Returns From AbbVie Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-23 06:16:00 | https://www.fool.com/investing/2022/09/23/what-could-this-drug-news-mean-for-abbvie/ | AbbVie recently submitted a regulatory application in the European Union for Rinvoq to treat patients with a form of inflammatory bowel disease. | What Could This Drug News Mean for AbbVie? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2022-09-22 11:30:09 | https://marijuanastocks.com/top-medical-marijuana-stocks-to-buy-2-big-pharma-plays-in-cannabis/ | Could These Be Good Long Term Investments Into Cannabis? The post Top Medical Marijuana Stocks To Buy? 2 Big Pharma Plays In Cannabis appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Top Medical Marijuana Stocks To Buy? 2 Big Pharma Plays In Cannabis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-22 06:00:00 | https://www.fool.com/investing/2022/09/22/3-dividend-stocks-you-can-safely-hold-for-decades/ | These companies have solid track records -- and great prospects. | 3 Dividend Stocks You Can Safely Hold for Decades | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-22 05:37:00 | https://www.fool.com/investing/2022/09/22/do-back-to-back-approvals-make-this-biotech-stock/ | This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet. | Do Back-to-Back Approvals Make This Biotech Stock a Buy Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-09-21 10:32:13 | https://www.zacks.com/stock/news/1983015/is-trending-stock-abbvie-inc-abbv-a-buy-now | AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-09-20 13:33:11 | https://www.zacks.com/stock/news/1982750/abbvie-abbv-gets-chmp-nod-for-skyrizi-in-a-third-indication | The CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug is approved for treating plaque psoriasis and psoriatic arthritis indications. | AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-20 10:45:00 | https://www.fool.com/investing/2022/09/20/2-dividend-stocks-to-double-up-on-glaxo-abbvie/ | These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields. | 2 Dividend Stocks to Double Up On Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-09-19 23:05:15 | https://seekingalpha.com/article/4541956-abbvie-stock-humira-hurdle | AbbVie has a small hurdle to overcome the impact of the LOE on key drug Humira. The company remains on path for a nearly $12 EPS stream at the low point in 2023 and 2024. | AbbVie: Small Hurdle | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.